Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Tuesday issued an update
regarding its clinical development programs, manufacturing and strategy for
bringing its Oncoprex(TM) immunogene therapy to market. A corporate presentation is available on GNPX’s website
which details anticipated milestones and future guidance for the company.
“These milestones emphasize our commitment to developing potentially
life-changing gene technologies for cancer patients who need them most,” Genprex
chairman and chief executive officer Rodney Varner stated in the news release.
“We continue to dedicate our efforts toward developing Oncoprex for non-small
cell lung cancer (“NSCLC”) and we believe that achievement of these milestones
will enable us to advance our gene therapy platform and position us to bring
our drug candidate to commercialization.” In addition, GNPX this morning
announced that it will be presenting at the H.C. Wainwright 21st Annual Global
Investment Conference in New York City at 3:00 PM ET on Tuesday, September 10,
2019. Genprex chairman and chief executive officer Rodney Varner will lead the
presentation and will be available for one-on-one meetings. To set a meeting,
contact the company at Investors@Genprex.com.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s initial
product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung
cancer (NSCLC). Genprex’s platform technologies are designed to administer
cancer fighting genes by encapsulating them into nanoscale hollow spheres
called nanovesicles, which are then administered intravenously and taken up by tumor
cells where they express proteins that are missing or found in low quantities.
Oncoprex has a multimodal mechanism of action whereby it interrupts cell
signaling pathways that cause replication and proliferation of cancer cells,
re-establishes pathways for apoptosis, or programmed cell death, in cancer
cells, and modulates the immune response against cancer cells. Oncoprex has
also been shown to block mechanisms that create drug resistance. For more
information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
